Disease relapse in patients who entered the ISAV study. (A) Relapse-free survival (RFS) from imatinib discontinuation (months). (B) RFS according to different age groups. (a) <50 years (n = 30); (b) 50-59 years (n = 22); (c) 60-70 years (n = 25); (d) >70 years (n = 30). Log-rank test P < .001. (C) RFS according to dPCR results at the time of imatinib discontinuation.